Angiogenesis in vasculitides

Clinical and Experimental Rheumatology

Volumn 26, Issue 3, 2008, Pages 476-483

  Maruotti, Nicola ^a   Cantatore, Francesco P ^a   Nico, Beatrice ^b   Vacca, Angelo ^b   Ribatti, Domenico ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Inflammation; Vasculitides

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; COLONY STIMULATING FACTOR; HAPTOGLOBIN;

ANGIOGENESIS; AORTA ARCH SYNDROME; ARTERY INTIMA PROLIFERATION; BEHCET DISEASE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL WALL; BUERGER DISEASE; CHRONIC INFLAMMATION; ENDOTHELIUM CELL; FIBROSIS; GIANT CELL ARTERITIS; HUMAN; HYPOXIA; INFLAMMATORY DISEASE; ISCHEMIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; THROMBOGENESIS; VASCULITIS; WEGENER GRANULOMATOSIS;

BEHCET SYNDROME; GIANT CELL ARTERITIS; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEOVASCULARIZATION, PATHOLOGIC; THROMBOANGIITIS OBLITERANS; VASCULITIS;

EID: 48949117166     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. RISAU W: Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
2. PEPPER MS: Manipulating angiogenesis: from basic science to the bedside. Arter Thromb Vasc Biol 1997; 17: 605-19.
3. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
4. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
5. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
6. FIOCCHI C: Inflammatory bowel disease etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
7. BOUSVAROS A, LEICHTNER A, ZURAKOWSKI D et al.: Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 1999; 44: 424-30.
8. LEE SS, JOO YS, KIM WU et al.: Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 321-4.
9. CID MC, HERNÁNDEZ-RODRÍGUEZ J, ESTEBAN MJ et al.: Tissue and Serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106: 1664.
10. MEDINA J, SANZ-CAMENO P, GARCÍA-BUEY L, MARTÍN-VÍLCHEZ S, LÓPEZ-CABRERA M, MORENO-OTERO R: Evidence of angiogenesis in primary biliary cirrhosis: an immnunohistochemical descriptive study. J Hepatol 2005; 42: 124-31.
11. BALLARA SC, MIOTLA JM, PALEOLOG EM: New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 1999; 80: 235-50.
12. BIAN XW, CHEN JH, JIANG XF, BAI JS, WANG QL, ZHANG X: Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopharmacol 2004; 4: 1537-47.
13. CLAUSS M, GERLACH M, GERLACH H et al.: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
14. MELDER RJ, KOENIG GC, WITWER BP, SAFABAKHSH N, MUNN LL, JAIN RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-7.
15. FOLKMAN J, KLAGSBRUN M, SASSE J, WADZINSKI M, INGBER D, VLODAVSKY I: A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988; 130: 393-400.
16. BUCKLEY CD, AMFT N, BRADFIELD PF et al.: Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 2000; 165: 3423-9.
17. BUCKLEY CD, PILLING D, LORD JM, AKBAR AN, SCHEEL-TOELLNER D, SALMON M: Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22: 199-204.
18. MARUOTTI N, CANTATORE FP, CRIVELLATO E, VACCA A, RIBATTI D: Macrophages in rheumatoid arthritis. Histol Histopathol 2007; 22: 581-6.
19. SALEH A, STONE JH: Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol 2005; 19: 209-21.
20. COPEMAN PWM, RYAN TJ: The problems of classification of cutaneous angiitis with reference to histopathology and pathogenesis. Br J Dermatol 1970; 82: 2-14.
21. CEM AR M, SOYSAL T, HATEMI G, SALIHOGLU A, YAZICI H, ULKU B: Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 2005; 84: 609-13.
22. KOSSARD S: Defining lymphocytic vasculitis. Australas J Dermatol 2000; 41: 149-55.
23. HAMMAR SP: Granulomatous vasculitis. Semin Respir Infect 1995; 10: 107-20.
24. LUQMANI RA, ROBINSON H: Introduction to, and classification of the systemic vasculitides. Best Pract Res Clin Rheumatol 2001; 15: 187-202.
25. NIKKARI S, RELMAN A: Molecular approaches for identification of infectious agents in Wegener's granulomatosis. Curr Opin Rheumatol 1999; 11: 11-6.
26. SRIVASTAVA MD: Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease. Res Commun Mol Pathol Pharmacol 2001; 109: 125-41.
27. SRIVASTAVA MD, ALEXANDER F, TUTHILL RJ: Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005; 61: 329-36.
28. MANTOVANI A, BUSSOLINO F, DEJANA E: Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
29. COLL-VINENT B, CEBRIAN M, CID MC et al.: Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998; 41: 435-44.
30. SZEKANECZ A, SZEGEDI G, KOCH AE: Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med 1998; 46: 27-41.
31. CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
32. CID MC, CEBRIÁN M, FONT C et al.: Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte/ endothelial cell interactions. Arthritis Rheum 2000; 43: 184-94.
33. CID MC, ESPARZA J, JUAN M et al.: Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in beta 1 and beta 2 integrin function. Eur J Immunol 1994; 24: 1377-82.
34. CID MC, SEGARRA M, GARCIA-MARTINEZ A, HERNANDEZ-RODRIGUEZ J: Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep 2004; 6: 184-94.
35. NORDBORG E, NORDBORG C, MALMVALL BE, ANDERSSON R, BENGTSSON BA: Giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 1013-26.
36. HUNDER GG: Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997; 81: 195-219.
37. ESTEBAN MJ, FONT C, HERNÁNDEZ-RODRÍGUEZ J et al.: Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum 2001; 44: 1387-95.
38. SALVARANI C, CIMINO L, MACCHIONI P et al.: Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005; 53: 293-7.
39. GONZALES-GAY MA, GARCIA-PORRUA C, LLORCA J et al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283-92.
40. GONZALES-GAY MA, BARROS S, LOPEZ-DIAZ MJ, GARCIA-PORRUA C, SANCHEZ-ANDRADE A, LLORCA J: Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005; 84: 269-76.
41. WEYAND CM, HICOK KC, HUNDER GG, GORONZY JJ: Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994; 121: 484-91.
42. WEYAND CM, GORONZY JJ: Arterial wall injury in giant-cell arteritis. Arthritis Rheum 1999; 42: 844-53.
43. COLL-VINENT B, VILARDELL C, FONT C et al.: Circulating soluble adhesion molecules in patients with giant-cell arteritis: correlation between soluble intercellular adhesion molecule-1 (SCAM-1) and disease activity. Ann Rheum Dis 1999; 58: 189-92.
44. HERNÁNDEZ-RODRÍGUEZ I, GARCÍA-MARTÍNEZ A, CASADEMONT J et al.: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 29-35.
45. CID MC, GRANT DS, HOFFMAN GS, AUERBACH R, FAUCI AS, KLEINMAN HK: Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91: 977-85.
46. WEYAND CM, TETZLAFF N, BJORNSSON J, BRACK A, YOUNGE B, GORONZY JJ: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997; 40: 1926.
47. KAISER M, YOUNGE B, BJÖRNSSON J, GORONZY JJ, WEYAND CM: Formation of new vasa vasorum in vasculitis. Am J Pathol 1999; 155: 765-74.
48. GONZALES-GAY MA, HAJEER AH, DABABNEH A et al.: Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004; 22 (Suppl. 36): S18-20.
49. RUEDA B, LOPEZ-NEVOT MA, LOPEZ-DIAZ MJ, GARCIA-PORRUA C, MARTIN J, GONZALES-GAY MA: A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005; 32: 1737-41.
50. LIE JT: Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21: 883-909.
51. WEYAND CM, WAGNER AD, BJORNSSON J, GORONZY JJ: Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996; 98: 1642-9.
52. NIKKARI ST, HOYHTYA M, ISOLA J, NIKKARI T: Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996; 149: 1427-33.
53. KAISER M, WEYAND CM, BJORNSSON J, GORONZY JJ: Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623-33.
54. BAUMANN H, GAULDIE J: The acute phase response. Immunol Today 1994; 15: 74-80.
55. ROSSI V, BREVIARIO F, GHEZZI P, DEJANA E, MANTOVANI A: Prostacyclin synthesis induced by in vascular cells by interleukin-1. Science 1985; 225: 174-6.
56. MANTOVANI A, GARLANDA C, INTRONA M, VECCHI A: Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. Transplant Proc 1998; 30: 4239-43.
57. HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Circulation 2003; 107: 2428-34.
58. HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M, VILARDELL C et al.: Tissue production of proinflammatory cytokines (IL-1β, TNF-α, and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004; 43: 294-301.
59. IOZZO RV: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997; 32: 141-74.
60. NELIMARKKA L, SALMINEN H, KUOPIO T et al.: Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am J Pathol 2001; 158: 345-53.
61. SCHÖNHERR E, WITSCH-PREHM P, HARRACH B, ROBENEK H, RAUTERBERG J, KRESSE H: Interaction of biglycan with type I collagen. J Biol Chem 1995; 270: 2776-83.
62. SVENSSON L, HEINEGARD D, OLDBERG A: Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem 1995; 270: 20712-6.
63. LEWANDOWSKA K, CHOI HU, ROSENBERG LC, ZARDI L, CULP LA: Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol 1987; 105: 1443-54.
64. SCHMIDT G, ROBENEK H, HARRACH B et al.: Interaction of small dermatan sulfate proteoglycan from fibroblasts with fibronectin. J Cell Biol 1987; 104: 1683-91.
65. JACKSON CJ, JENKINS KL: Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 1991; 192: 319-23.
66. VERNON RB, LARA SL, DRAKE CJ et al.: Organized type I collagen influences endothelial patterns during "spontaneous angiogenesis in vitro": planar cultures as models of vascular development. In Vitro Cell Dev Biol Anim 1995; 31: 120-31.
67. JARVELAIMEN HT, IRUELA-ARISPE ML, KINSELLA MG, SANDELL LJ, SAGE EH, WIGHT TN: Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro. Exp Cell Res 1992, 203: 395-401.
68. IOZZO RV, MOSCATELLO DK, MC QUILLAN DJ, EICHSTETTER I: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999; 274: 4489-92.
69. SCHÖNHERR E, O'CONNELL BC, SCHITTNY J et al.: Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices. Eur J Cell Biol 1999; 78: 44-55.
70. HUTTENLOCHER A, WERB Z, TREMBLE P, HUHTALA P, ROSENBERG L, DAMSKY CH: Decorin regulates collagenase gene expression in fibroblasts adhering to vitronectin. Matrix Biol 1996; 15: 239-50.
71. SARTIPY P, JOHANSEN B, GASVIK K, HURT CAMEJO E: Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions. Circ Res 2000; 86: 707-14.
72. JACKSON JR, BOLOGNESE B, MANGAR CA, HUBBARD WC, MARSHALL LA, WINKLER JD: The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis. Biochim Biophys Acta 1998; 1392: 145-52.
73. MACH F, SCHONBECK U, FABUNMI RP et al.: T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-38.
74. O'CONNOR DS, SCHECHNER JS, ADIDA C et al.: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-8.
75. YAMAGUCHI Y, MANN DM, RUOSLAHTI E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281-4.
76. HILDEBRAND A, ROMARIS M, RASMUSSEN LM et al.: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994; 302: 527-34.
77. PENC SF, POMAHAC B, WINKLER T et al.: Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem 1998; 273: 28116-21.
78. NELIMARKKA L, SALMINEN H, KUOPIO T et al.: Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am J Pathol 2001; 158: 345-53.
79. FUJIWARA H, HAMASHIMA Y: Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61: 100-7.
80. AMANO S, HAZAMA F, HAMASHIMA Y: Pathology of Kawasaki disease: pathology and morphogenesis of the vascular changes. Jpn Circ J 1979; 43: 633-43.
81. KATO H, INOUE O, AKAGI T: Kawasaki disease: cardiac problems and management. Pediatr Rev 1988; 9: 209-17.
82. ROWLEY AH, SHULMAN ST: Kawasaki syndrome. Pediatr Clin North Am 1999; 46: 313-29.
83. NAOE S, TAKAHASHI K, MASUDA H, TANAKA N: Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn 1991; 41: 785-97.
84. GAVIN PJ, CRAWFORD SE, SHULMAN ST, GARCIA FL, ROWLEY AH: Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003; 23: 576-81.
85. MITCHELL RN, COTRAN RS: Repair: cell regeneration, fibrosis, and wound healing. In KUMAR V, COTRAN RS, ROBBINS SL (Eds.) Basic Pathology. 6th ed. Philadelphia: WB Saunders, 1997: 47-59.
86. TERAI M, YASUKAWA K, NARUMOTO S, TATENO S, OANA S, KOHNO Y: Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999; 83: 337-9.
87. CHUA PK, MELISH ME, YU Q, YANAGIHARA R, YAMAMOTO KS, NERURKAR VR: Elevated levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 2003; 10: 308-314.
88. MIURA M, GARCIA FL, CRAWFORD SE, ROWLEY AH: Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr Infect Dis J 2004; 23: 931-6.
89. NAM EJ, HAN SW, KIM SU et al.: Association of vascular endothelial growth factor gene polymorphisms with Behçet disease in a Korean population. Hum Immunol 2005; 66: 1068-73.
90. YACIN B, ARDA N, TEZEL GG, ERMAN M, ALLI N: 1Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behçet's disease. Anal Quant Cytol Histol 2006; 28: 303-6.
91. ERDEM H, PAY S, SERDAR M et al.: Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with BD, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. Rheumatol Int 2005; 26: 162-7.
92. BOZOGLU E, DINC A, ERDEM H, PAY S, SIMSEK I, KOCAR IH: Vascular endothelial growth factor and monocyte chemoattractant protein-1 in BD patients with venous thrombosis. Clin Exp Rheumatol 2005; 23: S42-8.
93. KÖTTER I, ZIERHUT M, ECKSTEIN AK et al.: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423-31.
94. BROUTY-BOYE D, ZETTER BR: Inhibition of cell motility by interferon. Science 1980; 208: 516-8.
95. HALACHEVA K, GULUBOVA MV, MANOLOVA I, PETKOV D: Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 2002; 104: 177-84.
96. KATZ SI: Inflammatory and neoplastic disorders of the dermis: Erythema elevatum diutinum. In FREEDBERG IM, EISEN AZ, WOLF K et al. (Eds.): Fitzpatrick's Dermatology in General Medicine, 5th ed. New York, McGraw-Hill 1993: 1: 1124.
97. LE BOIT PE, BENEDICT YEN TSB, WINTROUB B: The evolution of lesion in erythema elevatum diutinum. Am J Dermatopathol 1986; 8: 392.
98. NICKOLOFF BJ, GRIFFTHS CEM: The spindle-shaped cells in cutaneous Kaposi's sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes. Am J Pathol 1989; 135: 793-800.
99. PENNEYS SP: Factor XIII expression in the skin: observations and a hypothesis. J Am Acad Dermatol 1990; 22: 484-8.
100. PACHECO LS, SOTTO MN: Factor XIIIa+ dermal dendrocytes in erythema elevatum diutinum and ordinary cutaneous leukocyto-elastic vasculitis lesions. J Cutan Pathol 2000; 27: 136-40.
101. GALARIA NA, WERTH VP, SCHUMACHER HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041-4.
102. MC CAIN ME, QUINET RJ, DAVIS WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology 2002; 41: 116-7.
103. LIVERMORE PA, MURRAY KJ: Anti-tumor necrosis factor therapy associated with cutaneous vasculitis. Rheumatology 2002; 41: 1450-2.
104. SHAKOOR N, MICHALSKA M, HARRIS C, BLOCK J: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2003; 359: 579-80.
105. JARRETT SJ, CUNNANE G, CONAGHAN PG et al.: Antitumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287-91.
106. MC ILWAIN L, CARTER JD, BIN-SAGHEERS, VASEY FB, NORD J: Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003; 36: 411-3.
107. SEO SJ, FIELDS ML, BUCKLER JL et al.: The impact of T helper and T regulatory cells on the regulation of anti-double stranded DNA B cells. Immunity 2002; 16: 535-46.